ArticleArchives of microbiology2026
Elevated in vitro activity of ibrexafungerp against azole-resistant Candida isolates from Vulvovaginal Candidiasis (VVC): a multicentric study from India.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC) is complicated by an increase in non-albicans Candida (NAC) species, biofilm formation and rising fluconazole resistance, limiting the effectiveness of conventional therapies. Ibrexafungerp, a newer antifungal, offers a novel therapeutic option owing to its distinct mechanism of action against azole-resistant isolates. A total of 400 isolates from four centres (PGIMER, Chandigarh; RIMS, Imphal; BHU, Varanasi and MGMMC, Indore) were included in this study. Species identification was performed by MALDI-TOF MS, and antifungal susceptibility testing (AFST) as per Clinical and Laboratory Standards Institute (CLSI) M27 guidelines. Candida albicans was the most prevalent species across the four centres (72%, 74%, 34% and 47% from Chandigarh, Imphal, Varanasi and Indore respectively). Among NAC species, Nakaseomyces glabratus was predominant in Chandigarh (19%) and Imphal (14%), and Candida tropicalis in Varanasi (31%) and Indore (33%). AFST showed higher resistance in C. albicans to fluconazole - 11% in Chandigarh, 3% in Varanasi, and 2% in Imphal and Indore. C. tropicalis exhibited resistance to fluconazole and voriconazole amongst isolates from Varanasi only. Mutations in ERG11 gene attributing to azole-resistance included A114V, F145L amongst the fluconazole-resistant isolates. Biofilm formation of C. albicans was statistically significant in PGIMER compared to other centres. Ibrexafungerp MICs among C. albicans isolates ranged from 0.06 to 2 µg/ml, among C. tropicalis isolates from 0.12 to 1 µg/ml, among N. glabratus isolates from 0.25 to 1 µg/ml. With this, we derive that Candida albicans remains the predominant causative agent of VVC, however, NACs are increasing. Fluconazole is still the drug of choice to treat VVC, but with increasing resistance, the use of ibrexafungerp could be a promising alternative strategy.
Indexed as
Identifiers
42859206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.